stoxline Quote Chart Rank Option Currency Glossary
  
(NVAX)
  0 (0%)    03-29 05:41
Open:
High:
Volume: 0
  
Pre. Close:
Low:
Market Cap: 0(M)
Technical analysis
2024-03-28 4:53:16 PM
Short term     
Mid term     
Targets 6-month :  6.25 1-year :  7.06
Resists First :  5.35 Second :  6.05
Pivot price 4.97
Supports First :  4.23 Second :  3.51
MAs MA(5) :  4.76 MA(20) :  5.11
MA(100) :  5.04 MA(250) :  6.66
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  11.1 D(3) :  10.3
RSI RSI(14): 47.5
52-week High :  11.35 Low :  3.52
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NVAX ] has closed above bottom band by 28.4%. Bollinger Bands are 27.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.96 - 4.98 4.98 - 5
Low: 4.69 - 4.73 4.73 - 4.75
Close: 4.73 - 4.78 4.78 - 4.82
Company Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Headline News

Thu, 28 Mar 2024
Novavax Inc (NVAX) is down 1.03% Thursday In Premarket Trading - InvestorsObserver

Sat, 09 Mar 2024
1 Beaten-Down Stock That's Still Not Worth Buying - The Motley Fool

Thu, 07 Mar 2024
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street - Yahoo Finance

Sat, 02 Mar 2024
Earnings Update: Novavax, Inc. (NASDAQ:NVAX) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance

Wed, 28 Feb 2024
NVAX Stock Alert: 9 Reasons Why Novavax Investors Are So Disappointed Today - InvestorPlace

Wed, 28 Feb 2024
Novavax stock falls 20% as vaccine maker misses quarterly estimates, sees sluggish 2024 sales - CNBC

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 140 (M)
Shares Float 125 (M)
Held by Insiders 5 (%)
Held by Institutions 56.3 (%)
Shares Short 52,740 (K)
Shares Short P.Month 52,090 (K)
Stock Financials
EPS -5.41
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -5.14
Profit Margin -55.5 %
Operating Margin -63.1 %
Return on Assets (ttm) -17.1 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -18.5 %
Gross Profit (p.s.) 0
Sales Per Share 7.02
EBITDA (p.s.) -3.66
Qtrly Earnings Growth 0 %
Operating Cash Flow -714 (M)
Levered Free Cash Flow -979 (M)
Stock Valuations
PE Ratio -0.89
PEG Ratio 0
Price to Book value -0.93
Price to Sales 0.68
Price to Cash Flow -0.94
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android